...
首页> 外文期刊>Pathology oncology research: POR >CD44-SLC1A2 Fusion Transcripts in Primary Colorectal Cancer
【24h】

CD44-SLC1A2 Fusion Transcripts in Primary Colorectal Cancer

机译:CD44-SLC1A2融合转录本在原发性大肠癌中的作用

获取原文
获取原文并翻译 | 示例

摘要

A CD44-SLC1A2 fusion has recently been discovered in a subset of primary gastric cancers, and an APIP-SLC1A2 fusion has been described in a colon cancer cell line (SNU-C1); however, whether such SLC1A2 fusions occur in primary colorectal cancer (CRC) and whether such fusions are specific for gastrointestinal cancers remain uncertain. In the present study, we examined 90 primary CRCs and 112 primary non-small cell lung cancers (NSCLCs) for CD44-SLC1A2 and APIP-SLC1A2 fusion transcripts using RT-PCR and subsequent sequencing analyses. Although the expression of both types of SLC1A2 fusion transcripts was not detected in any of the NSCLCs, the expression of CD44-SLC1A2, but not the APIP-SLC1A2 fusion transcript, was detected in one (1.1 %) CRC. The CD44-SLC1A2 fusion transcript was expressed in cancerous tissue but not in corresponding non-cancerous tissue, and the fusion occurred between exon 1 of CD44 and exon 2 of SLC1A2; it was expected that a slightly truncated but functional SLC1A2 protein would be produced under the CD44 promoter. A quantitative RT-PCR analysis revealed that SLC1A2 mRNA expression was upregulated in CRC containing SLC1A2 fusion transcripts, while it was downregulated in most other CRCs. The SLC1A2 fusion-positive carcinoma was located on the right-side of colon, was a mucinous adenocarcinoma, was immunohistochemically negative for MSH2 mismatch repair protein, and contained no APC or KRAS mutations. Together, these results suggest that the expression of SLC1A2 fusion transcripts is related to a subset of primary CRCs and may contribute to the elucidation of the characteristics of SLC1A2 fusion-positive CRCs in the future.
机译:最近在一部分原发性胃癌中发现了CD44-SLC1A2融合蛋白,在结肠癌细胞系(SNU-C1)中已经描述了APIP-SLC1A2融合蛋白。然而,这种SLC1A2融合是否发生在原发性结直肠癌(CRC)中以及这种融合是否对胃肠道癌具有特异性仍不确定。在本研究中,我们使用RT-PCR和随后的测序分析检查了CD44-SLC1A2和APIP-SLC1A2融合转录本的90例原发性CRC和112例原发性非小细胞肺癌(NSCLC)。尽管在任何NSCLC中均未检测到两种SLC1A2融合转录本的表达,但在一个(1.1%)CRC中检测到了CD44-SLC1A2的表达,但未检测到APIP-SLC1A2融合的转录本。 CD44-SLC1A2融合转录本在癌组织中表达,但在相应的非癌组织中不表达,融合发生在CD44的外显子1和SLC1A2的外显子2之间。预期在CD44启动子下会产生一个略微截短但功能正常的SLC1A2蛋白。定量RT-PCR分析显示,在包含SLC1A2融合转录本的CRC中,SLC1A2 mRNA表达上调,而在其他大多数CRC中,其表达下调。 SLC1A2融合阳性癌位于结肠的右侧,是粘液性腺癌,MSH2错配修复蛋白免疫组织化学阴性,不包含APC或KRAS突变。总之,这些结果表明SLC1A2融合转录本的表达与原发性CRC的一个子集有关,并且可能有助于将来阐明SLC1A2融合阳性CRC的特征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号